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Monitoring of Voriconazole (VRC) Blood Levels 
for Prevention of Serious Neurological Adverse 
Events (SNAE) 
A.A. Pascua[*, S. Bo[ay, O. Marchetti. CHUV, 
Lausanne, Switzerland 
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Sacral Zoster with Secondary Dissemination and 
Urinary Retention: A Case Report and Review of 
the Literature 
P. Meytan*. Institut de Microbiologie, CHUV, 
Lausanne, Switzerland 
Background: Voriconazote (VRC) is a widety 
used broad-spectrum antifunga[ agent. Non-linear 
pharmacokinetics, po[ymorphism of cytochrome 
CYP2C19, drug interactions and hepatic dysfunc- 
tion may result in inter- and intra-individua[ vari- 
ations of VRC brood revers. We reported SNAE 
probabty associated with protonged VRC overdosing 
(trough brood revers higher than 5.5 mg/L during 
more than 7d) (ICAAC 2005, M-2164). This obser- 
vation suggested that VRC close adjustment based 
on monitoring of brood revers may hetp to prevent 
SNAE. 
Objective: To prospectivety evatuate the utitity 
of monitoring VRC brood revers for prevention of 
SNAE. 
Methods: VRC trough brood revers were measured 
by HPLC during the first week of therapy in 25 con- 
secutive treatment courses during 2005. VRC dos- 
ing was adjusted if VRC trough brood revers were 
>5.5 mg/L. Clinical follow-up included surveillance 
for adverse events (NCI criteria). Occurrence of 
SNAE during VRC therapy in 2004 (no prospective 
close adjustment based on VRC brood revers) and 
2005 (prospective close adjustment) was compared. 
Results: Indications for VRC therapy were as- 
pergillosis (60%), candidiasis (16%), and suspected 
mycosis (24%). Median VRC close was 4 mg/kg bid 
(range 1.3-5.7). Median number of VRC trough 
brood revers measurements/treatment course was 
2.5 (range 1-5). Median clays to first measurement 
after starting VRC therapy were 2 (2-7). Nine pts 
(37%) presented transient self-limiting visual dis- 
turbances/hattucinations. Two patients (8%) pre- 
sented severe hepatotoxicity. Occurrence of SNAE 
in 2004 and 2005 is compared in the tabte. 
2004 2005 
Pts with VRC trough [eve[ >5.5 mglL 8•32 (25%) 5•25 (20%) 
Median days >5.5mglL (range) 12.5 (6-30)* 4 (4-7) 
SNAE 4•32 (12%) 0125(0%) 
*P=0.05. 
Conclusions: These prospective data corroborate 
our pretiminary report that rapid dose adjust- 
ment in patients with VRC brood revers exceeding 
5.5 mg/L may hetp to prevent serious neurotogica[ 
adverse events. Further observations are needed 
to confirm this finding. 
Background: A 52 year otd patient with tow grade 
non Hodgkin [ymphoma known since 2000 had 
received conventiona[ chemotherapy unti[ 2002. 
Upon [ymphoma progression, he underwent 5 cures 
of fludarabine/rituximab/cyctophosphamide chemo 
therapy from September 2004 to January 2005 that 
resutted in comptete remission. Two months be- 
fore admission, tota[ [ymphs were 456 cetts/mm 3, 
CD4+ 115 and CDg+ 228. Ten clays before admis- 
sion, a crop of painfu[ vesictes appeared on the 
right buttock, in a $4 crescent distribution. A 
few days tater, disseminated vesictes started to 
appear on the whore body. Ora[ vatacictovir was 
initiated but vesicles continued to appear which 
ted to the admission of the patient three days 
tater. The physica[ inctuding the neurotogica[ exam, 
was unremarkabte except for cutaneous findings. 
Brood cet[ count and chemistry were unremark- 
able. Acic[ovir (2 x 10 mg/kg/d) was administered. 
Within 3 days, no new [esions were noticed, but 
the $4 right dermatome presented as a shattow 
confluent utceration with a fibrinous exudate in the 
intergtutea[ area. Five days after admission, the 
patient presented a urinary retention that required 
urethra[ catheterisation. Absent right achittean and 
patettar eflexes, and paresthesias on the right 
thigh and buttock were observed. Retrospectivety, 
he mentioned that he had had difficutties with 
micturition since the appearance of the vesictes. 
Conclusions: Urinary retention is a wet[ described 
comptication of sacra[ zoster. PuNished case re- 
ports suggest hat in a majority of cases, bradder 
function recovers within a few weeks. This condi- 
tion shoutd thus be treated by transient urethra[ 
catheterization. 
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Long-term Management and Safety of Oral 
Posaconazole for Progressive Zygomycosis 
in a Pediatric Oncology Patient Following 
Ambisome Intolerance 
A. Kheradpour*, N. G[over. Loma Linda University 
Children's Hospital, Loma Linda, CA, USA 
Background: Rhino-orbitocerebra[ mucormycosis is 
known to cause fata[ infection and severe morbid- 
ity in immunocompromised patients. The feasibility 
and safety of high dose posaconazo[e in a child 
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with leukemia and extensive mucor infection was 
evatuated. 
Methods: Pre-B acute tymphobtastic teukemia was 
diagnosed in a 3-year-old mate in June 2002. Dur- 
ing induction treatment he presented with fever, 
periorbita[ swelling and a black lesion on his 
hard palate with subsequent pathology positive 
for invasive zygomycosis. MRI of the head and or- 
bits showed extensive bony destruction of frontat, 
maxittary, sphenoid and nasa[ bone with devet- 
opment of infittrating masses within the orbits. 
After extensive surgicat resection and debride- 
ment, he started on amphotericin B and shortty 
after switched to [iposoma[ amphotericin. MRI of 
the head showed progression of the infection and 
frontat robe cerebritis consistent with direct spread 
of the disease during treatment with high dose 
ambisome. The patient devetoped hypertension, 
etevated creatinine, pending renat faiture; treat- 
ment was switched from ambisome to posacona- 
zo[e on compassionate basis in December 2002, and 
7 months tater ambisome was added three times a 
week. The patient has continued on posaconazote 
for the past three years with days of interruptions 
due to chemotherapy, specificatty, vinca atkatoid. 
At 2 years into treatment he patient suffered 
teukemia retapse. 
Results: The patient was successfutty managed 
with high dose posaconazote 200mg three times 
a day for a period of 7 months with no major 
toxicity and stable disease in spite of being treated 
with high dose chemotherapy. Patient atso toter- 
ated the combination of ambisome three times a 
week with high dose posaconazo[e fairly wet[. In 
spite of retapse for teukemia and intensification 
of chemotherapy we were abte to continue ambi- 
some and posaconazote and keep the mucor under 
control MRI of head two years post treatment 
showed resotution of most of the previousty ab- 
normal findings, and a limited biopsy did not show 
any fungat etements. Currentty the patient is in 
second remission for teukemia nd on maintenance 
chemotherapy with 200 mg posaconazote wo times 
a day. 
Conclusion: Our case is a good exampte of a 
very compticated case of mucor infection with 
teukemia. We were abte to manage both issues of 
leukemia nd mucor with no major morbidity, with 
acceptabte [eve[ of toxicity of mitd to moderate 
facial disfiguration white keeping bilateral vision 
intact. 
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A Prospective French National Survey to Assess 
Renal Safety of Amphotericin B lipid Complex 
and Liposomal Amphotericin B 
F. Sa[iba 1 *, N. Cheron 2, Ph. Ichai I, A. Renault 3, 
A. Sirvent 4, S. Depi[ s, B. Sau[quin 6, B. Witz 7, 
S. Visanca , O. Bastien 9, S. Gui[[aumin 1°. 1AP-HP, 
HOpital Paul Brousse, UniversitO Paris Sud, 
Villejui[, France, 2Centre medical Bligny, Briis- 
sous-Forges, France, 3HOpital Curule blanche, 
Brest, France, 4HOpital Archet, Nice, France, 
5HOpital Huriez, Lille, France, 6HOpital HOtel 
Dieu, Nantes, France, ZHOpital Brubois, Nuncy, 
France, 8HOpital Notre Dame Bon Secours, Metz, 
France, 9HOpital Cardiologique, Lyon, France, 
l°Laboratoires Zeneus Pharma, France 
Purpose: Lipid-based amphotericin B formulations 
(LF) have been recommended to treat patients 
suffering from renat insufficiency. We report a 
prospective mutticentre survey to assess renat 
function in adult patients treated for funga[ in- 
fections with LF: Abe[cet ® (ABLC) and AmBisome ® 
(C-Amb). 
Description: 88 patients (43 F, 45 M) with a mean 
age of 49.64-14 years were inctuded and evatuabte 
for renat safety. 44% of patients had neutrope- 
nia <500mm 3. 60 patients were treated with ABLC 
(median dose: 4.8 mg/kg/day) and 28 patients with 
L-Amb (median dose: 3.3mg/kg/day). The mean 
duration of treatment was 13.5+8 days for ABLC 
and 15+11 days for L-Amb. 68% of the patients 
received 2 or more nephrotoxic drugs (72% for 
ABLC; 61% for L-Amb). 
Creatininemia 0~mo[/L) Median Creatinine clearance (m[/min) 
(range) Median (range) 
Baseline End of therapy Baseline End of therapy 
At[ patients 84.0 111.5 89.5 60.8 
(n=88) [38.0;465.0] [31.0;363.0] [17.2;172.2] [22.1;207.0] 
Abe[cet 81.3 115.0 94.6 89.5 
(n =60) [38.0; 465.0] [45.0; 241.6] [17.2; 172.2] [22.1; 183.0] 
Ambisome 88.8 106.0 85.2 71.6 
(n =28) [42.0; 356.0] [31.0; 363.0] [21.5; 145.6] [24.0; 207.0] 
Results: No significant change occurred be- 
tween median serum creatinine [eve[ at baseline 
(81.3 ~mo[/[ 38.0; 465.0], 88.8 ~mo[/[ 42.0; 356.0]) 
and at end of therapy (115.0 ~mo[/[ [45.0; 241.6], 
106.0 ~mo[/[ [31.0; 363.0]), respectively, for ABLC 
and L-Amb. No significant change occurred be- 
tween median creatinine clearance at baseline 
(94.6 and 85.2m[/mn) and end of therapy (60.4 
and 71.6 m[/mn), respectively, for ABLC and 
L-Amb. In the group of 26 patients with re- 
nat insufficiency prior to treatment, no signifi- 
cant difference was found between median crea- 
tinine [eve[ and creatinine clearance at baseline 
